A chronic inflammatory condition known as non-radiographic axial spondyloarthritis (axSpA) remained undetectable on X-ray for most people with active disease who were on treatment with Cosentyx (secukinumab) for up to two years. That’s according to new data from PREVENT (NCT02696031), a Phase 3 clinical study that also showed sustained…
Anxiety and depression, but not resilience, were found to be linked to poorer overall health and functioning in people with axial spondyloarthritis (axSpA) — mostly men and almost all Chinese — who took part in a study done by researchers in Singapore. “Clinicians could consider routinely screening for anxiety and…
Amgen’s Amjevita, the first biosimilar to Humira (adalimumab) to receive approval by the U.S. Food and Drug Administration, is now available in the U.S. for the treatment of ankylosing spondylitis (AS) and other diseases. While the medication was initially approved in 2016, Amjevita is only now reaching…
Alvotech has launched a Phase 1 clinical trial to test the safety and efficacy of AVT05, its biosimilar drug candidate to Simponi (golimumab) — being developed for the treatment of ankylosing spondylitis (AS) and other diseases marked by inflammation. The study (NCT05632211) is enrolling more than…
Health Canada has approved a high-concentration formulation of Hadlima (adalimumab-bwwd), a biosimilar to Humira (adalimumab), for treating ankylosing spondylitis (AS) and other diseases. A biosimilar is a medical product designed to be identical — with similar properties, as well as comparable safety and effectiveness — to an…
Engaging in online yoga classes, or tele-yoga, may help people with ankylosing spondylitis (AS) relieve pain, overcome some functional limitations, and improve their mental health, a study from India suggests. The study, “Tele-yoga in the management of ankylosing spondylitis amidst COVID pandemic: A prospective randomized controlled trial,” was…
People with ankylosis spondylitis (AS) may not be at an increased risk of developing severe symptoms of COVID-19, according to a large U.S. study. That’s not the case, however, with those with rheumatoid arthritis, another immune-mediated disease, who were found to have a 20% higher risk of developing severe…
Sudo Biosciences has secured $37 million in series A financing to back the development of TYK2 inhibitors as potential anti-inflammatory medicines for immune-mediated inflammatory conditions, such as ankylosing spondylitis (AS). The goal, the company said in a press release announcing the new funding, is to move the…
Get regular updates to your inbox.